Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
3.940
+0.050 (1.29%)
At close: Aug 13, 2026, 4:00 PM EDT
3.940
0.00 (0.00%)
After-hours: Aug 13, 2026, 4:10 PM EDT

Protara Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
23.5621.9217.4518.6220.7426.4
Research & Development
53.2342.6331.724.9916.8121.09
Other Operating Expenses
----29.52-
Total Operating Expenses
76.7964.5549.1543.6167.0647.49
Operating Income
-76.79-64.55-49.15-43.61-67.06-47.49
Interest Income
6.536.384.173.191.110.24
Other Non-Operating Income (Expense)
7.037.844.953.191.110.24
Total Non-Operating Income (Expense)
13.5514.229.126.392.220.47
Pretax Income
-63.24-50.33-40.04-37.23-64.84-47.02
Net Income
-70.02-57.44-44.6-40.42-65.95-47.25
Net Income to Common
-70.02-57.44-44.6-40.42-65.95-47.25
Net Income Growth
------
Shares Outstanding (Basic)
524321111111
Shares Outstanding (Diluted)
524321111111
Shares Change
57.02%108.02%81.73%0.64%0.24%55.28%
EPS (Basic)
-1.35-1.34-2.17-3.57-5.86-4.21
EPS (Diluted)
-1.35-1.34-2.17-3.57-5.86-4.21
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-66.49-56.46-35.87-37.6-26.58-35.1
Free Cash Flow Growth
------
Free Cash Flow Per Share
-1.29-1.32-1.74-3.32-2.36-3.12
EBITDA
-76.45-64.19-48.82-43.27-66.81-47.37
EBIT
-76.79-64.55-49.15-43.61-67.06-47.49
SEC Filings: 10-K · 10-Q